Form 3: KLRS CFO Matthew Gall discloses zero beneficial ownership

Rhea-AI Filing Summary

Kalaris Therapeutics (KLRS) reported an insider ownership update. Chief Financial Officer Matthew Gall filed a Form 3 on 11/03/2025, the initial statement of beneficial ownership. The filing states that no securities are beneficially owned. This is an administrative disclosure and does not reflect any transaction or change in the company’s capital.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gall Matthew

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE SUITE 5500

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/03/2025

3. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Matthew Gall	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kalaris Therapeutics (KLRS) disclose in this filing?

A Form 3 was filed by the CFO, reporting no securities beneficially owned.

Who filed the Form 3 for KLRS and what is their role?

Matthew Gall, the company’s Chief Financial Officer, filed the Form 3.

When was the event requiring the Form 3 for KLRS?

The event date is 11/03/2025.

Does the Form 3 show any KLRS share ownership?

No. The filing states no securities are beneficially owned.

Is this filing a transaction for KLRS stock?

No. It is an administrative insider disclosure with no transaction reported.

What form type was filed for KLRS?

A Form 3, the initial statement of beneficial ownership by an insider.